These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 28630196)

  • 41. Methicillin-resistant Staphylococcus aureus (MRSA) nasal carriage among patients with diabetes at the Korle Bu Teaching Hospital.
    Anafo RB; Atiase Y; Kotey FCN; Dayie NTKD; Tetteh-Quarcoo PB; Duodu S; Osei MM; Alzahrani KJ; Donkor ES
    PLoS One; 2021; 16(9):e0257004. PubMed ID: 34534230
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Antimicrobial Activities of Ceftaroline and Comparator Agents against Bacterial Organisms Causing Bacteremia in Patients with Skin and Skin Structure Infections in U.S. Medical Centers, 2008 to 2014.
    Sader HS; Flamm RK; Mendes RE; Farrell DJ; Jones RN
    Antimicrob Agents Chemother; 2016 Apr; 60(4):2558-63. PubMed ID: 26856825
    [TBL] [Abstract][Full Text] [Related]  

  • 43. In vitro activity of ceftaroline against mecC-positive MRSA isolates.
    Armengol-Porta M; Tenorio-Abreu A; Bandt D; Coleman DC; Gavier-Widen D; Hotzel H; Kinnevey P; Lazaris A; Peters M; Rangstrup-Christensen L; Schlotter K; Shore AC; Ehricht R; Monecke S
    J Glob Antimicrob Resist; 2016 Jun; 5():3-6. PubMed ID: 27436457
    [TBL] [Abstract][Full Text] [Related]  

  • 44.
    Pfaller MA; Sader HS; Rhomberg PR; Flamm RK; Mendes RE
    Microb Drug Resist; 2019; 25(6):938-943. PubMed ID: 30694735
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Staphylococcus aureus keratitis: a review of hospital cases.
    Ong SJ; Huang YC; Tan HY; Ma DH; Lin HC; Yeh LK; Chen PY; Chen HC; Chuang CC; Chang CJ; Hsiao CH
    PLoS One; 2013; 8(11):e80119. PubMed ID: 24244625
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Nationwide surveillance of resistance rates of Staphylococcus aureus clinical isolates from Greek hospitals, 2012-2013.
    Souli M; Karaiskos I; Galani L; Maraki S; Perivolioti E; Argyropoulou A; Charissiadou A; Zachariadou L; Tsiplakou S; Papaioannou V; Tsorlini H; Katsifa H; Baka V; Pantazi P; Paschali A; Kyratsa A; Trikka-Graphakos E; Giannopoulou P; Vogiatzakis E; Moraitou H; Papadogeorgaki H; Avgerinou H; Panagea T; Pantazatou A; Petinaki E; Stamatopoulou G; Toutouza M; Karatzoglou I; Kontopoulou K; Orfanidou M; Karantani I; Fytas P; Tzanetou K; Platsouka E; Kazila P; Chli A; Statiri N; Giamarellou H
    Infect Dis (Lond); 2016 Apr; 48(4):287-292. PubMed ID: 26635179
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Molecular characterization and antibiotic resistance of clinical isolates of methicillin-resistant Staphylococcus aureus obtained from Southeast of Iran (Kerman).
    Sadeghi J; Mansouri S
    APMIS; 2014 May; 122(5):405-11. PubMed ID: 24033803
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Ceftaroline fosamil: a cephalosporin with activity against methicillin-resistant Staphylococcus aureus.
    Poon H; Chang MH; Fung HB
    Clin Ther; 2012 Apr; 34(4):743-65. PubMed ID: 22444785
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Ceftaroline: clinical and microbiology experience with focus on methicillin-resistant Staphylococcus aureus after regulatory approval in the USA.
    Stryjewski ME; Jones RN; Corey GR
    Diagn Microbiol Infect Dis; 2015 Mar; 81(3):183-8. PubMed ID: 25583130
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Hospital-acquired Staphylococcus aureus infections at Texas Children's Hospital, 2001-2007.
    Hultén KG; Kaplan SL; Lamberth LB; Slimp K; Hammerman WA; Carrillo-Marquez M; Starke JR; Versalovic J; Mason EO
    Infect Control Hosp Epidemiol; 2010 Feb; 31(2):183-90. PubMed ID: 20001603
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Molecular Epidemiology of Staphylococcus aureus among Patients with Skin and Soft Tissue Infections in Two Chinese Hospitals.
    Gu FF; Chen Y; Dong DP; Song Z; Guo XK; Ni YX; Han LZ
    Chin Med J (Engl); 2016 Oct; 129(19):2319-24. PubMed ID: 27647191
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Comparison table: some antibiotics for MRSA skin and skin structure infections.
    Med Lett Drugs Ther; 2018 Mar; 60(1543):e59-e62. PubMed ID: 29635269
    [No Abstract]   [Full Text] [Related]  

  • 53. Efficacy of human simulated exposures of ceftaroline administered at 600 milligrams every 12 hours against phenotypically diverse Staphylococcus aureus isolates.
    Keel RA; Crandon JL; Nicolau DP
    Antimicrob Agents Chemother; 2011 Sep; 55(9):4028-32. PubMed ID: 21670184
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Ceftaroline activity against bacterial organisms isolated from acute bacterial skin and skin structure infections in United States medical centers (2009-2011).
    Pfaller MA; Flamm RK; Sader HS; Jones RN
    Diagn Microbiol Infect Dis; 2014 Apr; 78(4):422-8. PubMed ID: 24445158
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Changing Susceptibility of Staphylococcus aureus in a US Pediatric Population.
    Sutter DE; Milburn E; Chukwuma U; Dzialowy N; Maranich AM; Hospenthal DR
    Pediatrics; 2016 Apr; 137(4):. PubMed ID: 26933211
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Analysis of Staphylococcus aureus clinical isolates with reduced susceptibility to ceftaroline: an epidemiological and structural perspective.
    Alm RA; McLaughlin RE; Kos VN; Sader HS; Iaconis JP; Lahiri SD
    J Antimicrob Chemother; 2014 Aug; 69(8):2065-75. PubMed ID: 24777906
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Update on the in vitro activity of ceftaroline against Staphylococcus aureus from United States (US) medical centers stratified by infection type (2018-2020).
    Sader HS; Castanheira M; Duncan LR; Mendes RE
    Diagn Microbiol Infect Dis; 2023 Jan; 105(1):115820. PubMed ID: 36274343
    [TBL] [Abstract][Full Text] [Related]  

  • 58.
    Pfaller MA; Mendes RE; Duncan LR; Flamm RK; Sader HS
    Antimicrob Agents Chemother; 2018 Feb; 62(2):. PubMed ID: 29158271
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Trimethoprim-sulfamethoxazole or clindamycin for community-associated MRSA (CA-MRSA) skin infections.
    Frei CR; Miller ML; Lewis JS; Lawson KA; Hunter JM; Oramasionwu CU; Talbert RL
    J Am Board Fam Med; 2010; 23(6):714-9. PubMed ID: 21057066
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Synergy between gemifloxacin and trimethoprim/sulfamethoxazole against community-associated methicillin-resistant Staphylococcus aureus.
    Leonard SN; Kaatz GW; Rucker LR; Rybak MJ
    J Antimicrob Chemother; 2008 Dec; 62(6):1305-10. PubMed ID: 18801920
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.